🔴 LIVE — Updated every 10 minutes
👤 -- reading now 🌡 Nairobi
Breaking
HomeFinanceGSK Agrees to Buy Nuvalent for…
Finance

GSK Agrees to Buy Nuvalent for $10.6 Billion

Bloomberg Jun 9, 2026 1h ago ⏱ 1 min read 👁 2 views
GSK Agrees to Buy Nuvalent for $10.6 Billion
Image via Bloomberg
📋 Article Summary
83 words
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.… GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Continue Reading
Full story on Bloomberg
Read Full Story →
🔗 Clicking will take you to www.bloomberg.com
Share this story: WhatsApp X/Twitter Facebook
👁 People Also Read
8.1 Magnitude Quake Strikes Philippines, Tsunami Waves Possible
Finance

8.1 Magnitude Quake Strikes Philippines, Tsunami Waves Possible

An earthquake of 8.1 magnitude struck Mindanao, Philippines on Monday, according to the Helmholtz Centre for Geosciences. The quake had…

Read
Rep Steube Discusses Concerns Over Acting DNI Head
Finance

Rep Steube Discusses Concerns Over Acting DNI Head

President Trump has appointed Bill Pulte as the Acting Director of National Intelligence which has mixed reactions from lawmakers on…

Read
US Stock Futures Drop After Tech Selloff, Oil Up: Markets Wrap
Finance

US Stock Futures Drop After Tech Selloff, Oil Up: Markets Wrap

Equities looked set for more losses after a tech-led selloff on Wall Street Friday and a robust jobs report fueled…

Read
KE
AI’s Mega Stock Deals Raise Specter of More Shares Than Buyers
Finance

AI’s Mega Stock Deals Raise Specter of More Shares Than Buyers

A flood of new shares from companies looking to fund their artificial intelligence ambitions is raising questions on Wall Street…

Read